382591: Nakae Kazuto/Masui Sho/Yonezawa Atsushi/Hashimoto Motomu/Watanabe Ryu/Murata Koichi/Murakami Kosaku/Tanaka Masao/Ito Hiromu/Yokoyama Kotoko/Iwamoto Noriko/Shimada Takashi/Nakamura Miyuki/[傳田将也]/Itohara Kotaro/Nakagawa Shunsaku/Ikemi Yasuaki/Imai Satoshi/Nakagawa Takayuki/Hayakari Makoto/Matsubara Kazuo/Potential Application of Measuring Serum Infliximab Levels in Rheumatoid Arthritis Management: A Retrospective Study based on KURAMA Cohort Data/[PLoS ONE]

著作: Nakae Kazuto/Masui Sho/Yonezawa Atsushi/Hashimoto Motomu/Watanabe Ryu/Murata Koichi/Murakami Kosaku/Tanaka Masao/Ito Hiromu/Yokoyama Kotoko/Iwamoto Noriko/Shimada Takashi/Nakamura Miyuki/[傳田将也]/Itohara Kotaro/Nakagawa Shunsaku/Ikemi Yasuaki/Imai Satoshi/Nakagawa Takayuki/Hayakari Makoto/Matsubara Kazuo/Potential Application of Measuring Serum Infliximab Levels in Rheumatoid Arthritis Management: A Retrospective Study based on KURAMA Cohort Data/[PLoS ONE]

ヘルプを読む

「著作」（著作（著書，論文，レター，国際会議など））は，研究業績にかかる著作（著書，論文，レター，国際会議など）を登録するテーブルです． (この情報が属するテーブルの詳細な定義を見る)

項目名の部分にマウスカーソルを置いて少し待つと，項目の簡単な説明がツールチップ表示されます．

この情報をEDB閲覧画面で開く

EID: 382591
EOID: 1023062
Map: 0
LastModified: 2021年11月4日(木) 16:39:48
Operator: 大家隆弘
Avail: TRUE
Censor: 0
Owner: 傳田将也
Read: 継承
Write: 継承
Delete: 継承

種別

必須

学術論文(審査論文)

言語

必須

英語

招待

推奨

審査

推奨

カテゴリ

推奨

研究

共著種別

推奨

国内共著(徳島大学内研究者と国内(学外)研究者との共同研究 (国外研究者を含まない))

学究種別

推奨

組織

推奨

著者

必須

(英) Nakae Kazuto

役割任意

貢献度任意

学籍番号推奨
(英) Masui Sho

役割任意

貢献度任意

学籍番号推奨
(英) Yonezawa Atsushi

役割任意

貢献度任意

学籍番号推奨
(英) Hashimoto Motomu

役割任意

貢献度任意

学籍番号推奨
(英) Watanabe Ryu

役割任意

貢献度任意

学籍番号推奨
(英) Murata Koichi

役割任意

貢献度任意

学籍番号推奨
(英) Murakami Kosaku

役割任意

貢献度任意

学籍番号推奨
(英) Tanaka Masao

役割任意

貢献度任意

学籍番号推奨
(英) Ito Hiromu

役割任意

貢献度任意

学籍番号推奨
(英) Yokoyama Kotoko

役割任意

貢献度任意

学籍番号推奨
(英) Iwamoto Noriko

役割任意

貢献度任意

学籍番号推奨
(英) Shimada Takashi

役割任意

貢献度任意

学籍番号推奨
(英) Nakamura Miyuki

役割任意

貢献度任意

学籍番号推奨
傳田将也([徳島大学.大学院医歯薬学研究部.薬学域.先端薬学教育研究プロジェクト]/[徳島大学.大学院医歯薬学研究部.薬学域.薬科学部門.創薬科学系.機能分子合成薬学])

役割任意

貢献度任意

学籍番号推奨
(英) Itohara Kotaro

役割任意

貢献度任意

学籍番号推奨
(英) Nakagawa Shunsaku

役割任意

貢献度任意

学籍番号推奨
(英) Ikemi Yasuaki

役割任意

貢献度任意

学籍番号推奨
(英) Imai Satoshi

役割任意

貢献度任意

学籍番号推奨
(英) Nakagawa Takayuki

役割任意

貢献度任意

学籍番号推奨
(英) Hayakari Makoto

役割任意

貢献度任意

学籍番号推奨
(英) Matsubara Kazuo

役割任意

貢献度任意

学籍番号推奨

題名

必須

(英) Potential Application of Measuring Serum Infliximab Levels in Rheumatoid Arthritis Management: A Retrospective Study based on KURAMA Cohort Data

副題

任意

要約

任意

(英) Infliximab (IFX) therapy has considerably improved the treatment of rheumatoid arthritis (RA). However, some patients still do not respond adequately to IFX therapy, or the efficacy of the treatment diminishes over time. Although previous studies have reported a relationship between serum IFX levels and therapeutic efficacy, the potential applications of IFX therapeutic drug monitoring (TDM) in clinical practice remain unclear. The purpose of this study was to investigate the potential applications of IFX TDM by analyzing a Japanese cohort database. Data were collected retrospectively from the Kyoto University Rheumatoid Arthritis Management Alliance cohort between January 1, 2011, and December 31, 2018. Serum IFX levels were measured using a liquid chromatography-tandem mass spectrometer. Out of the 311 RA patients that used IFX, 41 were eligible for the analysis. Serum IFX levels were significantly higher in responders than in non-responders. An optimal cut-off value was determined to be 0.32 μg/mL based on a receiver operating characteristic curve. At the IFX measurement point, a better therapeutic response was observed in the high IFX group (n = 32) than in the low IFX group (n = 9). Conversely, at the maximum effect point, when DAS28-ESR was the lowest between IFX introduction and measurement points, there were no differences in responder proportions between the low and high IFX groups. IFX primary ineffectiveness could be avoided with appropriate dose escalation without blood concentration measurement in clinical practice. In conclusion, IFX TDM could facilitate the identification of secondary non-responders and in turn, proper IFX use.

キーワード

推奨

(英) Infliximab
(英) Rheumatoid Arthritis
(英) KURAMA Cohort

発行所

推奨

誌名

必須

PLoS ONE(Public Library of Science)

(eISSN: 1932-6203)

ISSN	任意	1932-6203 ISSN: 1932-6203 (eISSN: 1932-6203) Title: PloS one Title(ISO): PLoS One Publisher: PLOS (NLM Catalog) (Scopus) (CrossRef) (Scopus information is found. [need login])

巻

必須

号

必須

頁

必須

e0258601 e0258601

都市

任意

年月日

必須

2021年 10月 13日

URL

任意

DOI

任意

10.1371/journal.pone.0258601 (→Scopusで検索)

PMID

任意

34644354 (→Scopusで検索)

CRID

任意

WOS

任意

Scopus

任意

評価値

任意

被引用数

任意

指導教員

推奨

備考

任意

(英) Article.ELocationID: 10.1371/journal.pone.0258601
(英) Article.PublicationTypeList.PublicationType: Journal Article
(英) CoiStatement: M.H., R.W., K.Murata, M.T., and H.I. are associated with a department financially supported by two local governments in Japan (Nagahama City, Shiga and Toyooka City, Hyogo) and five pharmaceutical companies (Mitsubishi Tanabe Pharma Corp., Chugai Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corp., Asahi Kasei Pharma Corp., and UCB Japan Co., Ltd.). A.Y. and K.Matsubara has received a research grant from Shimadzu Corporation. M.H. received a research grant and/or speaker fee from Bristol-Myers Squibb Co., Eisai Co., Ltd., Eli Lilly Japan K.K., and Mitsubishi Tanabe Pharma Corp. R.W. has received speaker's fee from Mitsubishi Tanabe Pharma Corp., Pfizer Inc., Sanofi K.K., AbbVie GK, Asahi-Kasei Corp., Eisai Co., Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb Co., and Janssen Pharmaceutical K.K. K.Murata received a speaking fee from Eisai Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Astellas Pharma Inc. M.T. has received research grants and/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Corp., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Novartis Pharma K.K., Pfizer Inc., Taisho Pharma Co., Ltd., and UCB Japan Co., Ltd. H.I. has received a research grant and/or speaker fees from Bristol-Myers Squibb Co., Eisai Co., Ltd., Taisho Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Asahi Kasei Corp. The other authors declare no conflicts of interest.

徳島大学教育・研究者情報データベース(EDB)

Education and Research Database (EDB), Tokushima University